BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 32475062)

  • 1. Comparison of Wait-List Mortality Between Cholangiocarcinoma and Hepatocellular Carcinoma Liver Transplant Candidates.
    Ziogas IA; Hickman LA; Matsuoka LK; Izzy M; Montenovo MI; Rega SA; Feurer ID; Alexopoulos SP
    Liver Transpl; 2020 Sep; 26(9):1112-1120. PubMed ID: 32475062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival.
    Mehta N; Dodge JL; Roberts JP; Yao FY
    J Hepatol; 2021 Apr; 74(4):829-837. PubMed ID: 33188904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes for liver transplant candidates listed with low model for end-stage liver disease score.
    Kwong AJ; Lai JC; Dodge JL; Roberts JP
    Liver Transpl; 2015 Nov; 21(11):1403-9. PubMed ID: 26289624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increasing Liver Transplantation Wait-List Dropout for Hepatocellular Carcinoma With Widening Geographical Disparities: Implications for Organ Allocation.
    Mehta N; Dodge JL; Hirose R; Roberts JP; Yao FY
    Liver Transpl; 2018 Oct; 24(10):1346-1356. PubMed ID: 30067889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Racial Disparities in Candidates for Hepatocellular Carcinoma Liver Transplant After 6-Month Wait Policy Change.
    Saberi B; Gurakar A; Tamim H; Schneider CV; Sims OT; Bonder A; Fricker Z; Alqahtani SA
    JAMA Netw Open; 2023 Nov; 6(11):e2341096. PubMed ID: 37917059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unfair Advantages for Hepatocellular Carcinoma Patients Listed for Liver Transplant in Short-Wait Regions Following 2015 Hepatocellular Carcinoma Policy Change.
    Brondfield MN; Dodge JL; Hirose R; Heimbach J; Yao FY; Mehta N
    Liver Transpl; 2020 May; 26(5):662-672. PubMed ID: 31833634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Liver Transplant Wait-List Outcomes Among Patients With Hepatocellular Carcinoma With Public vs Private Medical Insurance.
    Gutin L; Yao F; Dodge JL; Grab J; Mehta N
    JAMA Netw Open; 2019 Aug; 2(8):e1910326. PubMed ID: 31469395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Projected outcomes of 6-month delay in exception points versus an equivalent Model for End-Stage Liver Disease score for hepatocellular carcinoma liver transplant candidates.
    Alver SK; Lorenz DJ; Marvin MR; Brock GN
    Liver Transpl; 2016 Oct; 22(10):1343-55. PubMed ID: 27343202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The race to liver transplantation: a comparison of patients with and without hepatocellular carcinoma from listing to post-transplantation.
    Patel MS; Kohn R; Kratz JR; Shah JA; Markmann JF; Vagefi PA
    J Am Coll Surg; 2015 Jun; 220(6):1001-7. PubMed ID: 25868408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Propensity-Matched Analysis of Patients with Mixed Hepatocellular-Cholangiocarcinoma and Hepatocellular Carcinoma Undergoing Liver Transplantation.
    Lunsford KE; Court C; Seok Lee Y; Lu DS; Naini BV; Harlander-Locke MP; Busuttil RW; Agopian VG
    Liver Transpl; 2018 Oct; 24(10):1384-1397. PubMed ID: 29573187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MELDEQ : An alternative Model for End-Stage Liver Disease score for patients with hepatocellular carcinoma.
    Marvin MR; Ferguson N; Cannon RM; Jones CM; Brock GN
    Liver Transpl; 2015 May; 21(5):612-22. PubMed ID: 25694099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients With Hepatocellular Carcinoma Have Highest Rates of Wait-listing for Liver Transplantation Among Patients With End-Stage Liver Disease.
    Goldberg D; French B; Newcomb C; Liu Q; Sahota G; Wallace AE; Forde KA; Lewis JD; Halpern SD
    Clin Gastroenterol Hepatol; 2016 Nov; 14(11):1638-1646.e2. PubMed ID: 27374003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact of Median Model for End-Stage Liver Disease at Transplant Minus 3 National Policy on Waitlist Outcomes in Patients With and Without Hepatocellular Carcinoma.
    Bernards S; Hirose R; Yao FY; Jin C; Dodge JL; Huang CY; Mehta N
    Liver Transpl; 2022 Mar; 28(3):376-385. PubMed ID: 34761847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era.
    Berg CL; Merion RM; Shearon TH; Olthoff KM; Brown RS; Baker TB; Everson GT; Hong JC; Terrault N; Hayashi PH; Fisher RA; Everhart JE
    Hepatology; 2011 Oct; 54(4):1313-21. PubMed ID: 21688284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver transplantation for hepatocellular carcinoma: the MELD impact.
    Sharma P; Balan V; Hernandez JL; Harper AM; Edwards EB; Rodriguez-Luna H; Byrne T; Vargas HE; Mulligan D; Rakela J; Wiesner RH
    Liver Transpl; 2004 Jan; 10(1):36-41. PubMed ID: 14755775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Racial/ethnic disparities in wait-list outcomes are only partly explained by socioeconomic deprivation among children awaiting liver transplantation.
    Wadhwani SI; Ge J; Gottlieb L; Lyles C; Beck AF; Bucuvalas J; Neuhaus J; Kotagal U; Lai JC
    Hepatology; 2022 Jan; 75(1):115-124. PubMed ID: 34387881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy.
    Mehta N; Dodge JL; Goel A; Roberts JP; Hirose R; Yao FY
    Liver Transpl; 2013 Dec; 19(12):1343-53. PubMed ID: 24285611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HEPATOCELLULAR CARCINOMA PATIENTS ARE ADVANTAGED IN THE CURRENT BRAZILIAN LIVER TRANSPLANT ALLOCATION SYSTEM. A COMPETING RISK ANALYSIS.
    Rodríguez S; Fleck AM; Mucenic M; Marroni C; Brandão A
    Arq Gastroenterol; 2020; 57(1):19-23. PubMed ID: 32294731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Waiting time predicts survival after liver transplantation for hepatocellular carcinoma: a cohort study using the United Network for Organ Sharing registry.
    Schlansky B; Chen Y; Scott DL; Austin D; Naugler WE
    Liver Transpl; 2014 Sep; 20(9):1045-56. PubMed ID: 24838471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors that affect deceased donor liver transplantation rates in the United States in addition to the Model for End-stage Liver Disease score.
    Sharma P; Schaubel DE; Messersmith EE; Guidinger MK; Merion RM
    Liver Transpl; 2012 Dec; 18(12):1456-63. PubMed ID: 22965903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.